Literatur: Abciximab

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Abciximab

  • 1. Anderson JL, Adams CD, Antman EM, et al, "2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Circulation, 2011, 123(18):e426-579. [PubMed 21444888]
  • 2. Antman EM, Anbe SC, Alpert JS, et al, “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” Circulation, 2004, 110(5):588-636. [PubMed 15289388]
  • 3. Antman EM, Hand M, Armstrong PW, et al, “2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” J Am Coll Cardiol, 2008, 51(2):210-49. [PubMed 18191746]
  • 4. Aguirre FV, Topol EJ, and Ferguson JJ, “Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Intergrin in Patients Undergoing Percutaneous Coronary Intervention. EPIC Investigators,” Circulation, 1995, 91(12):2882-90. [PubMed 7796496]
  • 5. Antman EM, Giugliano RP, Gibson CM, et al, “Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,” Circulation, 1999, 99(21):2720-32. [PubMed 10351964]
  • 6. “ASSENT-3 Investigators. Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction,” Lancet, 2001, 358 (9282):605-13. [PubMed 11530146]
  • 7. Berkowitz SD, Harrington RA, Rund MM, et al, “Acute Profound Thrombocytopenia After C7E3 Fab (Abciximab) Therapy,” Circulation, 1997, 95(4):809-13. [PubMed 9054735]
  • 8. Brener SJ, Barr LA, Burchenal JE, et al, “Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,” ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators, Circulation, 1998, 98(8):734-41. [PubMed 9727542]
  • 9. Ellis SG, Tendera M, de Belder MA, et al, “Facilitated PCI in Patients With ST-Elevation Myocardial Infarction,” N Engl J Med, 2008, 358(21):2205-17. [PubMed 18499565]
  • 10. Giugliano RP, “Drug-Induced Thrombocytopenia: Is It a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors?” J Thromb Thrombolysis, 1998, 5(3):191-202. [PubMed 10767115]
  • 11. Hamm CW, Heeschen C, Goldmann B, et al, “Benefit of Abciximab in Patients With Refractory Unstable Angina in Relation to Serum Troponin T Levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators,” N Engl J Med, 1999, 340(21):1623-9. [PubMed 10341274]
  • 12. Huxtable LM, Tafreshi MJ, and Rakkar AN, “Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,” Am J Cardiol, 2006, 97(3):426-9. [PubMed 16442410]
  • 13. Jubelirer SJ, Koenig BA, and Bates MC, “Acute Profound Thrombocytopenia Following C7E3 Fab (Abciximab) Therapy: Case Reports, Review of the Literature and Implications for Therapy,” Am J Hematol, 1999, 61(3):205-8. [PubMed 10398314]
  • 14. Kastrati A, Mehilli J, Neumann FJ, et al, “Abciximab in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment,” JAMA, 2006, 295(3):1531-8. [PubMed 16533938]
  • 15. Keeley EC, Boura JA, and Grines CL, “Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-elevation Myocardial Infarction: Quantitative Review of Randomised Trials,” Lancet, 2006, 367(9510):579-88. [PubMed 16488801]
  • 16. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al, “2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” J Am Coll Cardiol, 2008, 51(2):172-209. [PubMed 18191745]
  • 17. Kushner FG, Hand M, Smith SC, et al, “2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” J Am Coll Cardiol, 2009, 54(23):2205-41. [PubMed 19942100]
  • 18. Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Circulation, 2011, 124(23):e574-651. [PubMed 22064601]
  • 19. Lincoff AM, Califf RM, Anderson KM, et al, “Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications,” J Am Coll Cardiol, 1997, 30(1):149-56. [PubMed 9207636]
  • 20. Lincoff AM, Califf RM, Moliterno DJ, et al, “Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,” N Engl J Med, 1999, 341(5):319-27. [PubMed 10423466]
  • 21. Lincoff AM, Califf RM, Van de Werf F, et al, “Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction: GUSTO V Randomized Trial,” JAMA, 2002, 288(17):2130-5. [PubMed 12413372]
  • 22. Lincoff AM, Tcheng JE, Califf RM, et al, “Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial. Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade,” Circulation, 1999, 99(15):1951-8. [PubMed 10208997]
  • 23. Llevadot J, Coulter SA, and Giugliano RP, “A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,” J Thromb Thrombolysis, 2000, 9(2):175-80. [PubMed 10613999]
  • 24. Mascelli MA, Lance ET, Damaraju L, et al, “Pharmacodynamic Profile of Short-Term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery from GP IIb/IIIa Receptor Blockade,” Circulation, 1998, 97(17):1680-8. [PubMed 9591761]
  • 25. Moliterno DJ, Yakubov SJ, DiBattiste PM, et al, “Outcomes at 6 months for the Direct Comparison of Tirofiban and Abciximab During Percutaneous Coronary Revascularization With Stent Placement: The TARGET Follow-up Study.” Lancet, 2002, 360(9330):355-60. [PubMed 12241774]
  • 26. Osende JI, Fuster V, Lev EI, et al, “Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests: Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition,” Circulation, 2001, 103(11):1488-91. [PubMed 11257073]
  • 27. “Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin During Percutaneous Coronary Revascularization. The EPILOG Investigators,” N Engl J Med, 1997, 336(24):1689-96. [PubMed 9182212]
  • 28. “Randomised Placebo-Controlled Trial of Abciximab Before and During Coronary Intervention in Refractory Unstable Angina: The CAPTURE Study,” Lancet, 1997, 349(9063):1429-35. [PubMed 9164316]
  • 29. Schrör K and Weber A, “Comparative Pharmacology of GP IIb/IIIa Antagonists,” J Thromb Thrombolysis, 2003, 15(2):71-80 [PubMed 14618072]
  • 30. Sinnaeve PR, Alexander JH, Bogaerts K, et al, "Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction," Am Heart J, 2004, 147:993-8. [PubMed 15199346]
  • 31. Stone GW, Maehara A, Witzenbichler B, et al, “Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial," JAMA, 2012 [epub ahead of print]. [PubMed 22447888]
  • 32. Tcheng JE, Kereiakes DJ, Lincoff AM, et al, “Abciximab Readministration: Results of the ReoPro® Readministration Registry,” Circulation, 2001, 104(8):870-5. [PubMed 11514371]
  • 33. Thiele H, Wöhrle J, Hambrecht R, et al, “Intracoronary Versus Intravenous Bolus Abciximab During Primary Percutaneous Coronary Intervention in Patients With Acute ST-elevation Myocardial Infarction: A Randomised Trial,” Lancet, 2012 [epub ahead of print] [PubMed 22357109]
  • 34. Topol EJ, Ferguson JJ, Weisman HF, et al, “Long-Term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta3 Blockade With Percutaneous Coronary Intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication,” JAMA, 1997, 278(6):479-84. [PubMed 9256222]
  • 35. Topol EJ, GUSTO V Investigators, “Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,” Lancet, 2001, 357:1905-14. [PubMed 11425410]
  • 36. Topol E, Moliterno DJ, Herrmann HC, et al, “Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events With Percutaneous Coronary Revascularization,” N Engl J Med, 2001, 244:1888-94. [PubMed 11419425]
  • 37. Trivedi SM, Shani J, and Hollander G, “Bleeding Complications of Platelet Glycoprotein IIb/IIIa Inhibitor Abciximab (ReoPro®),” J Invasive Cardiol, 2002, 14(7):423-5. [PubMed 12082199]
  • 38. “Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty. The EPIC Investigation,” N Engl J Med, 1994, 330(14):956-61. [PubMed 8121459]
  • 39. Vahdat B, Canavy I, Fourcade L, et al, “Fatal Cerebral Hemorrhage and Severe Thrombocytopenia During Abciximab Treatment,” Catheter Cardiovasc Interv, 2000, 49(2):177-80. [PubMed 10642768]
  • 40. van den Merkhof LF, Zijlstra F, Olsson H, et al, “Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study,” J Am Coll Cardiol, 1999, 33(6):1528-32. [PubMed 10334418]
  • 41. Wandt H, Frank M, Ehninger G, et al, “Safety and Cost Effectiveness of a 10 X 109/L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 X 109/L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia,” Blood, 1998, 91(10):3601-6. [PubMed 9572994]
  • 42. Wright RS, Anderson JL, Adams CD, et al, "2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons," J Am Coll Cardiol, 2011, 57(19):1920-59. [PubMed 21450428]

 

  top |

 

 
Stand: 03/2017  |  © 2017 Prof. Dr. J. Braun